Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 3Gynecologic 1

Conditions

Solid Tumor 3Ovarian Neoplasms 1

Interventions

pembrolizumab 604Carboplatin 374Paclitaxel 283Cisplatin 270Gemcitabine 252Pemetrexed 194Bevacizumab 191Docetaxel 186Nivolumab 180Injections 169Cyclophosphamide 150atezolizumab 139Fluorouracil 134Capecitabine 133Oxaliplatin 132Dexamethasone 128durvalumab 113Fulvestrant 113130-nm albumin-bound paclitaxel 110fludarabine 103Cetuximab 100Leucovorin 97Rituximab 95venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 77Azacitidine 74Irinotecan 73Doxorubicin 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × senaparib × 1 year × Clear all
NCT04089189 2026-01-28

SABRINA

Impact Therapeutics, Inc.

Phase 2 Completed
93 enrolled
Gynecologic

Ovarian Neoplasms

NCT05390944 2025-09-16

An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition

Impact Therapeutics, Inc.

Phase 1 Completed
28 enrolled
Other solid neoplasm

Solid Tumor

NCT05391048 2025-09-16

An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition

Impact Therapeutics, Inc.

Phase 1 Completed
36 enrolled
Other solid neoplasm

Solid Tumor

NCT07030439 2025-06-22

A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State

Impact Therapeutics, Inc.

Phase 1 Completed
32 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡